Hair Relaxer Cancer Lawsuit MDL 3060 — 2026 Update

The question I hear most often about the hair relaxer lawsuit: “Is there actually any science behind it?”

Yes. And it comes from the National Institutes of Health.

In October 2022, researchers using data from the NIEHS Sister Study — one of the most rigorous women’s health cohort studies in U.S. history — published a peer-reviewed analysis showing that women who frequently used hair straightening products had approximately 2.5 times the risk of developing uterine cancer compared to non-users. Women who used relaxers four or more times per year had a 4.05% cumulative risk of developing uterine cancer by age 70, versus 1.64% for non-users.

That study (Chang et al., JNCI 2022, PMID: 36245087) is the scientific backbone of MDL 3060 — the hair relaxer cancer litigation now consolidated before Judge Mary Rowland in the Northern District of Illinois, with 11,371 plaintiffs and counting.

This guide covers the litigation structure, the science, your eligibility, and what to expect through 2027 when the first bellwether trials are anticipated.

This is informational, not legal advice. Consult a licensed attorney for your specific situation.

The Science: NIEHS Sister Study

Study Design and Key Findings

The Sister Study enrolled women aged 35–74 across the United States who had a sister with breast cancer, making the cohort unusually well-characterized for hormonal and environmental exposures.

Metric	Detail
Study name	NIEHS Sister Study
Participants	33,497 women
Follow-up	~11 years
Uterine cancer cases diagnosed	378
Frequent user risk increase	~2.5x (uterine cancer)
Ovarian cancer risk increase	~50% (frequent users)

The study controlled for multiple confounders including BMI, race, hormone therapy, and other cancer risk factors. The association between chemical hair straightener use and uterine cancer persisted after adjustment.

What Chemicals Are the Concern?

Three chemical categories have drawn the most scrutiny:

Phthalates are plasticizers that act as endocrine disruptors. They bind estrogen receptors and can interfere with the hormone signaling that governs uterine and ovarian tissue. Urine tests in exposed women have documented elevated phthalate metabolite levels.

Formaldehyde and formaldehyde-releasing agents — including DMDM hydantoin and quaternium-15, which appear in many relaxer formulations — are IARC Group 1 carcinogens (confirmed human carcinogens). The scalp’s dermal absorption rate is high, and the chemical straightening process often creates micro-abrasions that accelerate chemical uptake.

Parabens (methylparaben, propylparaben) are preservatives with documented estrogen receptor binding activity. Paraben concentrations have been measured in breast and uterine tissue samples in multiple studies.

The exposure pathway: scalp application → dermal absorption (high absorption rate, amplified by relaxer-related micro-abrasions) → systemic circulation → hormonal tissue.

Talcum powder ovarian cancer lawsuit comparison →

MDL 3060: Litigation Structure

Key Facts

Element	Detail
MDL Number	MDL 3060
Full Title	In re Hair Relaxer Marketing, Sales Practices, and Products Liability Litigation
Court	Northern District of Illinois
Judge	Mary Rowland
Plaintiff Count	~11,371 (April 2026)
MDL Size Ranking	3rd largest in the U.S.
Special Master	Ellen K. Reisman (settlement oversight)

Primary Defendants

• L’Oréal USA — Dark & Lovely, Ultra Sheen (largest defendant by market share)
• Revlon — in Chapter 11 bankruptcy, product liability covered by insurance
• Godrej Consumer Products — Just for Me brand
• Strength of Nature Global — Motions brand (formerly Namaste Labs)
• Namaste LLC — ORS Olive Oil line

Each defendant is tied to specific brands. Women who used multiple brands over the years may have claims against multiple defendants.

Timeline and Key Milestones

Date	Event
January 8, 2026	Science Day hearing before Judge Rowland
April 1, 2026	Daubert challenge motions due from defendants
April–June 2026	Bellwether fact discovery closes (June 10)
November 16, 2026	Daubert briefing and summary judgment motions complete
2027 (early–mid)	First bellwether trial anticipated

The Daubert Hearing: The Case’s Critical Inflection Point

The Daubert hearing — expected to be briefed and argued through late 2026 — is the pivot point for MDL 3060.

Under Daubert v. Merrell Dow Pharmaceuticals (509 U.S. 579, 1993) and Federal Rule of Evidence 702, federal judges serve as gatekeepers on expert testimony. The judge must find that the expert’s methodology is scientifically valid, that the reasoning is reliably applied to the facts, and that the testimony will assist the trier of fact.

In MDL 3060, defendants will challenge plaintiffs’ expert causation opinions on the grounds that:

• The NIEHS study shows correlation, not proven biological causation
• The chemical exposure pathway (scalp → systemic → reproductive hormones → cancer) lacks dose-response data
• Confounding variables were not fully controlled

Plaintiffs will argue that:

• The NIEHS study is methodologically rigorous and peer-reviewed
• Phthalate endocrine disruption is established toxicology
• IARC Group 1 classification of formaldehyde supports the causation theory

My read: If plaintiffs’ experts survive Daubert intact, the 2027 bellwether trials become a credible settlement pressure event. If Daubert results in significant expert exclusions, defendants gain negotiating leverage and the litigation timeline extends. The talc MDL 2738 spent years on Daubert disputes — that is the cautionary timeline for hair relaxer claimants.

Who Qualifies to File

Three Core Requirements

1. U.S. hair relaxer product use You must have used a qualifying chemical hair straightener or relaxer product sold in the United States, with regular, sustained use. Courts generally look for use spanning at least one year with multiple applications.

Evidence you should compile:

• Product names and brands used
• Approximate frequency and duration of use
• Salon receipts or records (if professionally applied)
• Personal purchase records
• Statements from family members who recall your product use

2. Uterine or ovarian cancer diagnosis Official medical records — pathology report, surgical notes, oncologist records — are required. Qualifying diagnoses include endometrial carcinoma, uterine sarcoma, and ovarian carcinoma subtypes.

3. Causal connection opportunity Your exposure history needs to align with the cancer theory — i.e., sustained frequent use, particularly during your reproductive years, preceding your diagnosis.

Comparative Analysis: Hair Relaxer vs. Talc vs. Roundup

Factor	Hair Relaxer MDL 3060	Talc MDL 2738	Roundup MDL 2741
Primary injury	Uterine cancer, ovarian cancer	Ovarian cancer, mesothelioma	Non-Hodgkin lymphoma
Science basis	NIEHS Sister Study (PMID 36245087)	IARC Group 1 asbestos	IARC Group 2A glyphosate
Daubert status	In progress (2026)	Extended disputes	Cleared (Hardeman)
Bellwether status	Not yet held (2027 expected)	Ongoing	3 plaintiff wins completed
Settlement	None	None (J&J bankruptcy)	Partial ($10.9B+, Bayer)
Plaintiff demographics	Predominantly Black women	Mixed race/gender	Agricultural workers (male-majority)
Defendants	L’Oréal, Revlon, others	Johnson & Johnson	Bayer (Monsanto)

The race dimension of MDL 3060 matters for trial strategy. The evidence suggests that chemical relaxers were disproportionately marketed to Black women. If plaintiff attorneys successfully frame this as targeted marketing of a harmful product to a specific community, that narrative carries weight with urban Illinois juries and influences settlement leverage.

Statute of Limitations by State

State	Period	Accrual Rule
California	2 years	Discovery rule (diagnosis or knowledge of link)
New York	3 years	From discovery of injury
Texas	2 years	From diagnosis
Florida	4 years	From discovery
Illinois	2 years	From discovery (MDL state)
Georgia	2 years	From discovery

A woman diagnosed with uterine cancer in 2021 in California likely has a deadline problem — but the discovery rule can toll the clock if she could not reasonably have connected her hair relaxer use to her diagnosis until the NIEHS study became public in October 2022. Every situation is fact-specific.

Worked Scenarios

Scenario A: Longtime Relaxer User, Uterine Cancer Diagnosis (Illinois)

Diane T., 54. Used L’Oréal Dark & Lovely relaxer every 6–8 weeks from 1990 to 2018. Diagnosed with stage II endometrial carcinoma in January 2023, treated with surgery and radiation.

• Use history: 28 years, every 6–8 weeks (6–8x/year) — well above the 4x/year threshold in the NIEHS study
• Diagnosis: Endometrial carcinoma — primary qualifying condition
• SOL: Illinois 2 years from January 2023 → deadline January 2025. If no complaint filed, may be time-barred. However, discovery rule argument possible if she didn’t connect relaxers to cancer until NIEHS publicity. Verify immediately.
• Defendant: L’Oréal USA primarily
• Assessment: Strong on merits, timing urgent

Scenario B: Multiple Brands, Ovarian Cancer (Florida)

Maria J., 47. Used various brands — Just for Me (Godrej), ORS (Namaste), and Motions (Strength of Nature) — from 1998 to 2015. Diagnosed with ovarian carcinoma in 2024.

• Use history: ~17 years, multiple brands, estimated 4–6x/year
• Diagnosis: Ovarian carcinoma — qualifying under MDL 3060 theory
• SOL: Florida 4 years from 2024 → deadline 2028 (not urgent)
• Defendants: Multiple (Godrej, Namaste, Strength of Nature)
• Assessment: Good window; ovarian cancer claim slightly weaker than uterine cancer claim in current scientific framing, but within the MDL scope

How to Move Forward

MDL 3060 is heading into its most consequential phase: Daubert briefing through 2026, then bellwether trials in 2027. The time to file a complaint and get into the MDL queue is before the first verdict.

Steps to take now:

1. Write down every hair relaxer product you used, the approximate timeframe, and how often
2. Request copies of all relevant medical records
3. Consult with a mass tort attorney who has active MDL 3060 cases — initial consultation is free
4. Ask about statute of limitations in your specific state before any other question
5. Look up your state bar’s referral program or AAJ (American Association for Justice) at justice.org

Roundup non-Hodgkin lymphoma MDL guide → Asbestos and mesothelioma compensation → Wrongful death settlement structures →

---

The Race Dimension of MDL 3060

MDL 3060 carries a dimension that distinguishes it from nearly every other mass tort in recent history: the plaintiffs are overwhelmingly Black women.

Marketing records in the litigation show that chemical relaxer brands specifically targeted Black women and girls, often promoting the products in communities where natural hair was subject to professional and social stigma. Defendants generated significant revenue from products marketed almost exclusively to this demographic.

The legal significance: if plaintiff attorneys can demonstrate that defendants knew or should have known about the health risks from their chemical formulations yet continued marketing these products to a specific community without adequate warning, that narrative goes directly to the failure-to-warn theory — and to punitive damages.

Environmental justice framing is increasingly recognized in mass tort litigation. Several plaintiff attorneys in MDL 3060 have explicitly incorporated an environmental justice framework in their briefs, arguing that the demographic targeting of a historically marginalized group amplifies the defendants’ culpability. While jury instructions do not explicitly reference environmental justice, the factual narrative it creates can influence jury deliberations in Cook County (Chicago) federal court.

Understanding the Chemical Exposure Pathway in Detail

How Scalp Absorption Works

The scalp has one of the highest dermal absorption rates of any body surface — research has documented percutaneous absorption rates for lipophilic (fat-soluble) compounds that are substantially higher than forearm or abdomen skin. The reasons:

1. Higher density of hair follicles (which serve as direct conduits into the dermis)
2. Rich vascular supply directly beneath the scalp skin
3. Chemical relaxer application involves sustained contact (15–45 minutes per application)
4. The alkaline pH of relaxers disrupts the skin’s barrier function, further increasing permeability

When relaxer is applied, the hair shaft’s disulfide bonds are broken down chemically (the source of the “straightening” effect). This same process affects the scalp skin: the stratum corneum is weakened, microabrasions form at hair follicle bases, and dermal penetration of the chemical mixture increases dramatically.

PFAS-Like Properties of Phthalates

While phthalates are not classified as PFAS, they share a critical characteristic with PFAS: bioaccumulation. Phthalates are metabolized to phthalate monoesters and di-2-ethylhexyl phthalate (DEHP) metabolites that can be detected in urine. In women with frequent relaxer use, multiple studies have found elevated urinary phthalate metabolite concentrations, providing a biological marker that links product exposure to internal body burden.

This chain — from scalp application to detectable blood/urine biomarker to cancer diagnosis — is precisely the mechanistic chain that plaintiff experts will present in Daubert hearings.

Damages Available in Hair Relaxer Claims

Categories of Compensable Harm

If you prevail in a hair relaxer claim — either at bellwether trial or through a settlement program — the following damages categories are typically available:

Economic Damages

• Past medical expenses (surgery, chemotherapy, radiation, hormone therapy)
• Future projected medical costs (surveillance, hormone replacement, ongoing treatment)
• Lost wages (from time off work during treatment)
• Lost future earning capacity (if cancer or treatment caused permanent work limitations)
• Household services (costs of assistance needed during treatment)

Non-Economic Damages

• Physical pain and suffering (during treatment and ongoing)
• Emotional distress and mental anguish
• Loss of enjoyment of life
• Loss of fertility or reproductive capacity (for younger women with uterine surgery)
• Loss of consortium (spouse’s claim for impact on marital relationship)

Punitive Damages If the evidence shows the defendants knew of the health risks and concealed them, punitive damages may be available. In the J&J talc MDL, some individual trial verdicts included substantial punitive components. Mass tort global settlements typically include a punitive element baked into the aggregate settlement figure but rarely allocated separately.

Damages for Hysterectomy and Infertility

Women who underwent hysterectomy as a result of uterine cancer caused by hair relaxer exposure face the permanent loss of reproductive capacity. For women of reproductive age who had not yet completed their family or who never had the opportunity to try to conceive, this loss is profound.

Courts have recognized significant non-economic damages for loss of reproductive capacity. The age at diagnosis significantly affects valuation: a 28-year-old who undergoes hysterectomy may receive substantially higher non-economic damages than a 55-year-old in a similar medical situation, because the loss of the opportunity to have children carries greater weight in damages assessment.

L’Oréal’s Market Position and Litigation Strategy

L’Oréal USA, as the manufacturer of Dark & Lovely and Ultra Sheen, is the highest-profile defendant in MDL 3060 due to market share alone. L’Oréal’s parent company is French, which raises the question of how French-owned corporations handle American mass tort litigation — generally: through aggressive defense and, if necessary, large confidential settlement programs that avoid U.S. trial by jury.

L’Oréal’s likely litigation strategy based on comparable corporate defendant behavior:

1. Aggressively challenge plaintiffs’ scientific experts at Daubert
2. Argue individual causation weaknesses (not every plaintiff used the product frequently enough; other risk factors explain the cancer)
3. If Daubert is lost or partially lost, initiate settlement negotiations through back-channels
4. Seek a global resolution with a claims-made fund that caps total exposure

Understanding this strategy helps set realistic expectations: if Daubert is resolved in plaintiffs’ favor, L’Oréal’s incentive to settle rather than face jury after jury grows substantially.

How Bellwether Trials Will Shape MDL 3060

The bellwether trial process in MDL 3060 is not merely procedural — it is the most important determinant of what individual plaintiffs ultimately receive.

Why Bellwether Selection Matters

Judge Rowland took an unusual step: rather than letting parties pick entirely self-serving bellwether candidates, she personally selected 10 representative cases from the pool of 32. Her criteria included:

• Cases involving multiple defendants (testing the full defendant roster)
• Clear causation fact patterns (eliminating confounders that would distort the jury’s assessment of the core theory)
• Exclusion of cases with talc product overlaps that could distract from the hair relaxer theory
• Cases that would genuinely test the MDL’s core claim — whether repeated use of chemical relaxers caused reproductive cancers

This curated selection increases the probability that bellwether results will meaningfully inform settlement negotiations, rather than producing case-specific outlier verdicts.

What a Plaintiff Win Would Mean

A plaintiff win in the first bellwether trial would:

1. Validate the causation theory in front of a jury of peers — the most powerful signal possible
2. Trigger accelerated settlement negotiations under Special Master Reisman’s oversight
3. Establish a per-case damages reference point that defendant counsel cannot dismiss
4. Potentially unlock punitive damages discussions if the verdict includes punitives

The Roundup MDL model is instructive: after three consecutive plaintiff wins in bellwether trials, Bayer agreed to a global settlement program exceeding $10 billion. Hair relaxer plaintiff attorneys are explicitly targeting that precedent.

What a Defendant Win Would Mean

A defense win would:

1. Validate the Daubert challenges and give defendants leverage to limit or exclude plaintiff experts
2. Slow but not stop settlement negotiations — 11,000+ plaintiffs cannot be individually tried
3. Force plaintiff leadership to identify case-specific weaknesses and filter out claims that cannot satisfy causation requirements
4. Potentially bifurcate the MDL by cancer type (separating stronger uterine cancer claims from less-developed ovarian cancer claims)

Even in the talc MDL 2738, where J&J employed the aggressive Texas Two-Step bankruptcy strategy, litigation continued because the volume of claims created systemic pressure regardless of individual trial outcomes.

The Role of the Plaintiffs’ Steering Committee

In large MDLs, individual plaintiffs do not directly control the overall litigation strategy. The Plaintiffs’ Steering Committee (PSC) — a group of experienced plaintiff mass tort attorneys appointed by the judge — manages common discovery, expert retention, bellwether selection, and global settlement negotiations.

What this means for you as an individual plaintiff:

• Your attorney may or may not be on the PSC
• PSC members conduct depositions of L’Oréal executives, Revlon scientists, and other key witnesses on behalf of all plaintiffs
• PSC common work product benefits all plaintiffs; individual firms pay a portion of PSC costs from ultimate recoveries
• You retain the right to reject any global settlement and pursue individual trial, but this rarely happens in practice

The quality of PSC leadership matters enormously in MDL outcomes. MDL 3060’s PSC includes several attorneys with successful mass tort track records in similar litigation.

Hair Relaxer Product History: What the Internal Documents May Show

Mass tort litigation depends heavily on internal corporate documents obtained during discovery. In hair relaxer litigation, plaintiff discovery requests have targeted:

Ingredient Safety Files: Internal safety assessments of phthalate, formaldehyde, and paraben concentrations in relaxer formulations. Documents showing that safety teams flagged risks that were overridden by marketing decisions are critical to punitive damage claims.

Marketing Research Files: Documents showing that companies knew their products were predominantly used by Black women, and that they designed marketing campaigns specifically targeting this demographic, are relevant to the failure-to-warn theory.

Regulatory Correspondence: FDA correspondence about relaxer product ingredients, including any internal discussions about warning label adequacy, are high-priority discovery targets.

Toxicology Consulting Files: Documents from outside toxicology consultants hired to evaluate ingredient safety — and whether their recommendations were followed — can either support or undermine the plaintiffs’ theory depending on their content.

In previous mass torts (J&J talc, Roundup), internal documents showing corporate awareness of health risks while publicly denying them were among the most damaging evidence plaintiffs presented. Hair relaxer discovery is likely pursuing comparable document evidence.

Federal Tax Treatment

Under IRC § 104(a)(2), damages received on account of physical injuries or physical sickness are excluded from federal gross income. This applies to:

• Compensatory damages for medical expenses
• Compensatory damages for pain, suffering, and emotional distress attributable to physical injury
• Loss of earning capacity damages

What is NOT excluded:

• Punitive damages (fully taxable as ordinary income)
• Interest on the settlement (taxable)
• Emotional distress damages NOT arising from physical injury (taxable, though in cancer cases the physical injury connection is strong)

Medicaid Lien Resolution

If you received Medicaid coverage for cancer treatment, your state’s Medicaid agency holds a lien on your settlement proceeds. Under the Deficit Reduction Act of 2005 and subsequent Supreme Court decisions (Arkansas Dept. of Health and Human Services v. Ahlborn), the Medicaid lien cannot exceed the “medical care” portion of your recovery — a proportional limitation that plaintiff attorneys routinely negotiate.

The interplay of Medicare lien, Medicaid lien, and tax exclusion means that the “net” amount you receive from a gross settlement figure can vary significantly based on your personal coverage history. Your attorney should walk you through these deductions before you decide whether to accept a settlement offer.

---

This article provides general information only and is not legal advice. Statute of limitations deadlines vary by state and individual circumstances. If you have been diagnosed with uterine or ovarian cancer and have a hair relaxer use history, consult a qualified mass tort attorney promptly — a free initial consultation is standard practice in contingency-fee litigation.